Asston Pharmaceuticals Limited (BOM:544445)
India · Delayed Price · Currency is INR 99.75
+2.45 (2.52%)
At close: Sep 25, 2026
Asston Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 254.69 | 250.39 | 155.86 | 65.38 | 95.99 | |
Revenue Growth | 1.72% | 60.65% | 138.39% | -31.89% | 19.47% |
Cost of Revenue | 174.13 | 141.44 | 97.54 | 33.49 | 76.74 |
Gross Profit | 80.56 | 108.96 | 58.32 | 31.89 | 19.25 |
Selling, General & Admin | 32.24 | 19.38 | 8.81 | 5.93 | 6.18 |
Other Operating Expenses | 53.48 | 27.07 | 16.61 | 10.79 | 16.62 |
Operating Expenses | 88.96 | 46.86 | 25.92 | 17.09 | 22.89 |
Operating Income | -8.4 | 62.1 | 32.4 | 14.8 | -3.64 |
Interest Expense | -6.17 | -7.98 | -9.01 | -6.76 | -4.25 |
Interest & Investment Income | 1.55 | 0.87 | 1.21 | 0.51 | 0 |
Currency Exchange Gain (Loss) | 57.83 | -8 | -7.45 | 5.11 | 7.45 |
Other Non Operating Income (Expenses) | 1.62 | 0.47 | 1.02 | 0.47 | 2.02 |
EBT Excluding Unusual Items | 46.43 | 47.46 | 18.17 | 14.13 | 1.59 |
Gain (Loss) on Sale of Assets | -0.5 | 0.56 | - | - | - |
Other Unusual Items | - | 2.14 | - | - | - |
Pretax Income | 45.93 | 50.16 | 18.17 | 14.13 | 1.59 |
Income Tax Expense | 7.28 | 11.63 | 4.57 | 3.56 | 0.48 |
Net Income | 38.65 | 38.53 | 13.6 | 10.57 | 1.11 |
Net Income to Common | 38.65 | 38.53 | 13.6 | 10.57 | 1.11 |
Net Income Growth | 0.32% | 183.23% | 28.74% | 855.34% | 20.70% |
Shares Outstanding (Basic) | 8 | 6 | 6 | 6 | 0 |
Shares Outstanding (Diluted) | 8 | 6 | 6 | 6 | 0 |
Shares Change | 25.36% | 11.99% | - | 5783.59% | 18.98% |
EPS (Basic) | 4.92 | 6.14 | 2.43 | 1.89 | 11.63 |
EPS (Diluted) | 4.92 | 6.14 | 2.37 | 1.89 | 11.62 |
EPS Growth | -19.97% | 159.22% | 25.61% | -83.76% | 1.45% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -202.42 | -0.25 | -38.11 | -5.67 | -11.89 |
Free Cash Flow Per Share | -25.75 | -0.04 | -6.80 | -1.01 | -124.88 |
Gross Margin | 31.63% | 43.51% | 37.42% | 48.77% | 20.05% |
Operating Margin | -3.30% | 24.80% | 20.79% | 22.63% | -3.79% |
Profit Margin | 15.18% | 15.39% | 8.73% | 16.16% | 1.15% |
Free Cash Flow Margin | -79.48% | -0.10% | -24.45% | -8.67% | -12.38% |
EBITDA | -5.16 | 62.51 | 32.9 | 15.17 | -3.55 |
EBITDA Margin | -2.02% | 24.96% | 21.11% | 23.20% | -3.70% |
D&A For EBITDA | 3.24 | 0.41 | 0.51 | 0.37 | 0.08 |
EBIT | -8.4 | 62.1 | 32.4 | 14.8 | -3.64 |
EBIT Margin | -3.30% | 24.80% | 20.79% | 22.63% | -3.79% |
Effective Tax Rate | 15.85% | 23.19% | 25.14% | 25.20% | 30.40% |
Revenue as Reported | 315.84 | 256.1 | 158.41 | 71.92 | 105.55 |